Evofem Biosciences, Inc. 8-K

What Happened

• Evofem Biosciences, Inc. announced it and Windtree Therapeutics, Inc. mutually agreed to terminate their License and Supply Agreement (originally entered March 20, 2025 and amended March 28, 2025), effective March 13, 2026.
• The Agreement covered Windtree becoming a manufacturer and supplier of PHEXXI® (lactic acid, citric acid, and potassium bitartrate). The Termination Agreement was filed as Exhibit 10.1 to the Form 8-K.
• The filing states there are no termination or other fees payable in connection with the termination; certain customary survival provisions of the Agreement remain in effect.

Key Details

• Termination effective date: March 13, 2026.
• Original License & Supply Agreement dates: entered March 20, 2025; amended March 28, 2025.
• Product involved: PHEXXI® (lactic acid, citric acid, potassium bitartrate).
• No termination or other fees payable per the Termination Agreement; Termination Agreement filed as Exhibit 10.1.

Why It Matters

• This ends the arrangement under which Windtree would manufacture and supply PHEXXI for Evofem. That could affect where and how Evofem sources manufacturing for the product, though the filing does not disclose replacement plans or quantify any financial impact.
• Investors should note the company reported no termination fees, but also should monitor future disclosures for information on alternative supply arrangements, potential effects on product availability, and any impact on revenues or costs.